Journal Title：Translational Psychiatry

Psychiatry has suffered tremendously by the limited translational pipeline. Nobel laureate Julius Axelrod's discovery in 1961 of monoamine reuptake by pre-synaptic neurons still forms the basis of contemporary antidepressant treatment. There is a grievous gap between the explosion of knowledge in neuroscience and conceptually novel treatments for our patients. Translational Psychiatry bridges this gap by fostering and highlighting the pathway from discovery to clinical applications, healthcare and global health. We view translation broadly as the full spectrum of work that marks the pathway from discovery to global health, inclusive. The steps of translation that are within the scope of Translational Psychiatry include (i) fundamental discovery, (ii) bench to bedside, (iii) bedside to clinical applications (clinical trials), (iv) translation to policy and health care guidelines, (v) assessment of health policy and usage, and (vi) global health. All areas of medical research, including — but not restricted to — molecular biology, genetics, pharmacology, imaging and epidemiology are welcome as they contribute to enhance the field of translational psychiatry.

轉(zhuǎn)化渠道有限，給精神病學(xué)帶來了巨大的損失。諾貝爾獎(jiǎng)獲得者朱利葉斯·阿克塞爾羅德于 1961 年發(fā)現(xiàn)突觸前神經(jīng)元對(duì)單胺的再攝取，這仍然是當(dāng)代抗抑郁治療的基礎(chǔ)。神經(jīng)科學(xué)知識(shí)的爆炸式增長(zhǎng)與患者概念上新穎的治療方法之間存在著巨大的差距。轉(zhuǎn)化精神病學(xué)通過促進(jìn)和強(qiáng)調(diào)從發(fā)現(xiàn)到臨床應(yīng)用、醫(yī)療保健和全球健康的途徑來彌合這一差距。我們將轉(zhuǎn)化視為從發(fā)現(xiàn)到全球健康之路的全方位工作。轉(zhuǎn)化精神病學(xué)范圍內(nèi)的轉(zhuǎn)化步驟包括 (i) 基礎(chǔ)發(fā)現(xiàn)、(ii) 從實(shí)驗(yàn)室到臨床、(iii) 從臨床到臨床應(yīng)用（臨床試驗(yàn)）、(iv) 轉(zhuǎn)化為政策和醫(yī)療保健指南、(v) 評(píng)估衛(wèi)生政策和使用情況，以及 (vi) 全球健康。歡迎所有醫(yī)學(xué)研究領(lǐng)域，包括但不限于分子生物學(xué)、遺傳學(xué)、藥理學(xué)、成像和流行病學(xué)，因?yàn)樗鼈冇兄诖龠M(jìn)轉(zhuǎn)化精神病學(xué)領(lǐng)域的發(fā)展。

Translational Psychiatry創(chuàng)刊于2011年，由Springer Nature出版商出版，收稿方向涵蓋PSYCHIATRY全領(lǐng)域，在行業(yè)領(lǐng)域中學(xué)術(shù)影響力很大，屬于TOP期刊，國(guó)際一流期刊，關(guān)注度和專業(yè)度非常高，所以對(duì)原創(chuàng)文章要求創(chuàng)新性很高，過審難度很高，如果您有志于TOP期刊，建議關(guān)注此刊。平均審稿速度 23 Weeks ，影響因子指數(shù)5.8，該期刊近期沒有被列入國(guó)際期刊預(yù)警名單，廣大學(xué)者值得一試。